Tenax Therapeutics

NEWS

Business

BioSpace Movers & Shakers, Feb. 4

Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

February 3, 2022

9 min read

Alex Keown

Business

New CEOs Named at Two Biopharma Companies

Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.

July 8, 2021

2 min read

Vanessa Doctor, RN

IN THE PRESS

Bio NC

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application

February 6, 2024

7 min read

Bio NC

Tenax Therapeutics Announces Reverse Stock Split - December 29, 2023

December 29, 2023

5 min read

Bio NC

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

November 17, 2023

8 min read

FDA

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 13, 2023

7 min read

Bio NC

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

July 19, 2023

6 min read

Bio NC

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 31, 2023

7 min read

Bio NC

Tenax Therapeutics Provides 2023 Business Update

April 12, 2023

8 min read

Bio NC

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

March 22, 2023

6 min read

Deals

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

February 3, 2023

6 min read

Bio NC

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 1, 2023

6 min read

JOBS